Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a Novel 2+1 T-Cell Targeting Bispecific Antibody for Mesothelin-Expressing Cancers
zymeworks宣佈ZW171的新藥申請獲得FDA批准,ZW171是一種新型的2+1 T細胞靶向雙特異性抗體,可用於表達微小結構蛋白的癌症治療
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a Novel 2+1 T-Cell Targeting Bispecific Antibody for Mesothelin-Expressing Cancers
zymeworks宣佈ZW171的新藥申請獲得FDA批准,ZW171是一種新型的2+1 T細胞靶向雙特異性抗體,可用於表達微小結構蛋白的癌症治療
譯文內容由第三人軟體翻譯。